Table 3.
The Distribution of Patients with Advanced Gastric Cancer
| Characteristic | WMD | PD | PCC | Mixed carcinoma | Total | p-value* |
|---|---|---|---|---|---|---|
| No. of patients | 758 (37.2) | 404 (19.8) | 644 (31.6) | 230 (11.3) | 2,036 (100) | |
| Age, yr | 66.2±10.7 | 63.9±12.3 | 55.8±12.8 | 60.1±13.5 | 61.7±12.9 | <0.001 |
| Sex | <0.001 | |||||
| Male | 587 (77.4) | 290 (71.8) | 337 (52.3) | 140 (60.9) | 1,354 (66.5) | |
| Female | 171 (22.6) | 114 (28.2) | 307 (47.7) | 90 (39.1) | 682 (33.5) | |
| Size of tumor, cm | 4.6±2.3 | 5.9±2.7 | 6.8±4.2 | 5.6±3.1 | 5.7±3.3 | <0.001 |
| Location | <0.001 | |||||
| Upper | 211 (27.8) | 144 (35.6) | 262 (40.7) | 73 (31.7) | 690 (33.9) | |
| Middle | 123 (16.2) | 80 (19.8) | 175 (27.2) | 50 (21.7) | 428 (21.0) | |
| Lower | 424 (55.9) | 180 (44.6) | 207 (32.1) | 107 (46.5) | 918 (45.1) | |
| Lauren type† | <0.001 | |||||
| Intestinal | 758 (100) | 186 (46) | 2 (0.3) | 40 (17.4) | 986 (48.4) | |
| Diffuse | 0 | 195 (48.3) | 639 (99.2) | 146 (63.5) | 980 (48.1) | |
| Mixed | 0 | 23 (5.7) | 3 (0.5) | 43 (18.7) | 69 (3.4) | |
| Treatment | <0.001 | |||||
| Endoscopic | 35 (4.6) | 1 (0.2) | 2 (0.3) | 4 (1.7) | 42 (2.1) | |
| Operative | 723 (95.4) | 403 (99.8) | 642 (99.7) | 226 (98.3) | 1,994 (97.9) | |
| Tumor appearance† | <0.001 | |||||
| Borrmann I | 35 (4.9) | 9 (2.4) | 4 (0.7) | 6 (2.7) | 54 (2.8) | |
| Borrmann II | 130 (18.2) | 81 (21.8) | 10 (1.6) | 14 (6.2) | 235 (12.2) | |
| Borrmann III | 482 (67.3) | 256 (68.8) | 409 (67.4) | 173 (76.5) | 1,320 (68.7) | |
| Borrmann IV | 7 (1.0) | 17 (4.6) | 168 (27.7) | 27 (11.9) | 219 (11.4) | |
| Lymphatic invasion | 475 (65.7) | 283 (75.1) | 349 (56.5) | 166 (72.8) | 1,273 (65.4) | <0.001 |
| Venous invasion | 160 (22.2) | 93 (24.7) | 169 (27.3) | 40 (17.6) | 462 (23.8) | 0.016 |
| Perineural invasion | 373 (51.7) | 238 (63.1) | 525 (84.8) | 170 (74.6) | 1,306 (67.1) | <0.001 |
| T stage‡ | <0.001 | |||||
| 2 | 284 (37.5) | 92 (22.8) | 139 (21.6) | 83 (36.1) | 598 (29.4) | |
| 3 | 310 (40.9) | 170 (42.1) | 184 (28.6) | 71 (30.9) | 735 (36.1) | |
| 4a | 113 (14.9) | 108 (26.7) | 277 (43.0) | 71 (30.9) | 569 (27.9) | |
| 4b | 51 (6.7) | 34 (8.4) | 44 (6.8) | 5 (2.2) | 134 (6.6) | |
| Node metastasis | <0.001 | |||||
| Negative | 314 (41.4) | 131 (32.4) | 231 (35.9) | 50 (21.7) | 726 (35.7) | |
| Positive | 444 (58.6) | 273 (67.6) | 413 (64.1) | 180 (78.3) | 1,310 (64.3) | |
| Distant metastasis | 0.091 | |||||
| Negative | 731 (96.4) | 378 (93.6) | 607 (94.3) | 221 (96.1) | 1,937 (95.1) | |
| Positive | 27 (3.6) | 26 (6.4) | 37 (5.7) | 9 (3.9) | 99 (4.9) |
Data are presented as number (%) or mean±SD.
WMD, well-moderately differentiated; PD, poorly differentiated; PCC, poorly cohesive carcinoma.
*The p-values were calculated by Student t-test (for continuous variables) and the chi-square test (for categorical variables); †The total number was different because unknown or missing values were excluded from the percentage calculation; ‡The clinical stage was established according to the guidelines of the 8th American Joint Committee on Cancer.